Evidence map›Paper›PMID 42433565›Full record

ArticleQuantitative imaging in medicine and surgery2026

Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.

Lujie Li, Meicheng Chen, Ji Zhu, Ling Ma, Fangzeng Lin, Xiang-Min Li, Qiong Li, Ying Zhu

Abstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lujie Li *Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Meicheng Chen *Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ji Zhu *Department of Thoracic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Ling MaDepartment of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Fangzeng LinDepartment of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiang-Min LiDepartment of Radiology, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University, Huizhou, China.
Qiong LiDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ying ZhuDepartment of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prognosis varies among patients with early-stage lung adenocarcinoma (LUAD) even within the same clinical stage. This study aimed to evaluate the prognostic value of measurements of computed tomography (CT), circulating tumor cells (CTC), and their combinations in clinical stage I LUAD. Methods: This retrospective analysis included 183 patients at stage I peripheral LUAD who underwent preoperative thin-section chest CT and CTC detection. The maximal solid size to tumor ratio on axial image was measured by radiologists (R-MSSA%). The three-dimensional volume (3D-SV) and mass (3D-SM) of solid components were measured by deep learning, followed by calculation of the consolidation-to-tumor ratios of 3D-SV (3D-SV%) and 3D-SM (3D-SM%). The differences in recurrence rates or overall survival of CTC, CT measurements, and their combinations were compared. Multivariate Cox proportional hazards models were used to identify independent risk factors. Results: Our study results indicated that 3D-SM, 3D-SV, 3D-SM%, and CTC can stratify the recurrence risk in clinical stage I patients. For clinical stage IA patients with high values of 3D-SM, 3D-SV, R-MSSA%, or 3D-SM%, the recurrence risk showed no significant difference compared with stage IB patients. Furthermore, for stage IA patients stratified as high-risk by the integration of CTC with 3D-SM or 3D-SV, the prognosis was worse than that of stage IB patients. A model combining 3D-SM and CTC had a higher C-index [0.75; 95% confidence interval (CI): 0.70, 0.81] compared to that of 3D-SM or CTC alone. Conclusions: The integration of CTC and CT measurements can enhance the stratification ability for early-stage lung cancer patients and improve the prognosis prediction, especially for those at stage IA.

Indexed as

circulating tumor cells (CTC)computed tomography (CT)Lung adenocarcinoma (LUAD)prognosis

Identifiers

PMID42433565
PMCPMC13350680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.